Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome

Hideki Muramatsu, Hirotoshi Sakaguchi, Takashi Taga, Ken Tabuchi, Souichi Adachi, Masami Inoue, Toshiyuki Kitoh, Aiko Suminoe, Hiromasa Yabe, Eichi Azuma, Yoko Shioda, Atsushi Ogawa, Akitoshi Kinoshita, Hisato Kigasawa, Yuko Osugi, Kazutoshi Koike, Keisei Kawa, Koji Kato, Yoshiko Atsuta, Kazuko Kudo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95% confidence interval): 80.0% (20.4-96.9%) vs. 10.0% (0.6%-35.8%), P=0.039). Pediatr Blood Cancer 2014;61:925-927.

Original languageEnglish
Pages (from-to)925-927
Number of pages3
JournalPediatric Blood and Cancer
Volume61
Issue number5
DOIs
Publication statusPublished - May 2014
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Down Syndrome
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Fear
Survival Rate
Transplantation
Confidence Intervals
Conditioning (Psychology)
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Muramatsu, H., Sakaguchi, H., Taga, T., Tabuchi, K., Adachi, S., Inoue, M., ... Kudo, K. (2014). Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. Pediatric Blood and Cancer, 61(5), 925-927. https://doi.org/10.1002/pbc.24883

Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. / Muramatsu, Hideki; Sakaguchi, Hirotoshi; Taga, Takashi; Tabuchi, Ken; Adachi, Souichi; Inoue, Masami; Kitoh, Toshiyuki; Suminoe, Aiko; Yabe, Hiromasa; Azuma, Eichi; Shioda, Yoko; Ogawa, Atsushi; Kinoshita, Akitoshi; Kigasawa, Hisato; Osugi, Yuko; Koike, Kazutoshi; Kawa, Keisei; Kato, Koji; Atsuta, Yoshiko; Kudo, Kazuko.

In: Pediatric Blood and Cancer, Vol. 61, No. 5, 05.2014, p. 925-927.

Research output: Contribution to journalArticle

Muramatsu, H, Sakaguchi, H, Taga, T, Tabuchi, K, Adachi, S, Inoue, M, Kitoh, T, Suminoe, A, Yabe, H, Azuma, E, Shioda, Y, Ogawa, A, Kinoshita, A, Kigasawa, H, Osugi, Y, Koike, K, Kawa, K, Kato, K, Atsuta, Y & Kudo, K 2014, 'Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome', Pediatric Blood and Cancer, vol. 61, no. 5, pp. 925-927. https://doi.org/10.1002/pbc.24883
Muramatsu, Hideki ; Sakaguchi, Hirotoshi ; Taga, Takashi ; Tabuchi, Ken ; Adachi, Souichi ; Inoue, Masami ; Kitoh, Toshiyuki ; Suminoe, Aiko ; Yabe, Hiromasa ; Azuma, Eichi ; Shioda, Yoko ; Ogawa, Atsushi ; Kinoshita, Akitoshi ; Kigasawa, Hisato ; Osugi, Yuko ; Koike, Kazutoshi ; Kawa, Keisei ; Kato, Koji ; Atsuta, Yoshiko ; Kudo, Kazuko. / Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 5. pp. 925-927.
@article{687a57bc74b949d1a48754e9ee091422,
title = "Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95{\%} confidence interval): 80.0{\%} (20.4-96.9{\%}) vs. 10.0{\%} (0.6{\%}-35.8{\%}), P=0.039). Pediatr Blood Cancer 2014;61:925-927.",
author = "Hideki Muramatsu and Hirotoshi Sakaguchi and Takashi Taga and Ken Tabuchi and Souichi Adachi and Masami Inoue and Toshiyuki Kitoh and Aiko Suminoe and Hiromasa Yabe and Eichi Azuma and Yoko Shioda and Atsushi Ogawa and Akitoshi Kinoshita and Hisato Kigasawa and Yuko Osugi and Kazutoshi Koike and Keisei Kawa and Koji Kato and Yoshiko Atsuta and Kazuko Kudo",
year = "2014",
month = "5",
doi = "10.1002/pbc.24883",
language = "English",
volume = "61",
pages = "925--927",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome

AU - Muramatsu, Hideki

AU - Sakaguchi, Hirotoshi

AU - Taga, Takashi

AU - Tabuchi, Ken

AU - Adachi, Souichi

AU - Inoue, Masami

AU - Kitoh, Toshiyuki

AU - Suminoe, Aiko

AU - Yabe, Hiromasa

AU - Azuma, Eichi

AU - Shioda, Yoko

AU - Ogawa, Atsushi

AU - Kinoshita, Akitoshi

AU - Kigasawa, Hisato

AU - Osugi, Yuko

AU - Koike, Kazutoshi

AU - Kawa, Keisei

AU - Kato, Koji

AU - Atsuta, Yoshiko

AU - Kudo, Kazuko

PY - 2014/5

Y1 - 2014/5

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95% confidence interval): 80.0% (20.4-96.9%) vs. 10.0% (0.6%-35.8%), P=0.039). Pediatr Blood Cancer 2014;61:925-927.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95% confidence interval): 80.0% (20.4-96.9%) vs. 10.0% (0.6%-35.8%), P=0.039). Pediatr Blood Cancer 2014;61:925-927.

UR - http://www.scopus.com/inward/record.url?scp=84895745117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895745117&partnerID=8YFLogxK

U2 - 10.1002/pbc.24883

DO - 10.1002/pbc.24883

M3 - Article

C2 - 24302531

AN - SCOPUS:84895745117

VL - 61

SP - 925

EP - 927

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -